Short Interest in Nuvilex Inc. (NASDAQ:PMCB) Increases By 356.3%

Nuvilex Inc. (NASDAQ:PMCB) saw a large growth in short interest during the month of May. As of May 15th, there was short interest totaling 469,898 shares, a growth of 356.3% from the April 30th total of 102,979 shares. Based on an average trading volume of 382,797 shares, the short-interest ratio is presently 1.2 days. Currently, 4.9% of the company’s stock are sold short.

Nuvilex Stock Performance

NASDAQ:PMCB opened at $0.83 on Friday. The firm has a market capitalization of $8.96 million, a price-to-earnings ratio of -0.75 and a beta of 0.46. Nuvilex has a 52-week low of $0.63 and a 52-week high of $1.51. The stock has a fifty day moving average of $0.75 and a 200 day moving average of $0.78.

Wall Street Analyst Weigh In

Several research firms have commented on PMCB. Wall Street Zen upgraded shares of Nuvilex to a “sell” rating in a research note on Saturday, January 31st. Weiss Ratings reissued a “sell (d)” rating on shares of Nuvilex in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Nuvilex Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.